Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;11(1):59-62.
doi: 10.3892/ol.2015.3843. Epub 2015 Oct 29.

High mobility group box 1 regulates tumor metastasis in cutaneous squamous cell carcinoma via the PI3K/AKT and MAPK signaling pathways

Affiliations

High mobility group box 1 regulates tumor metastasis in cutaneous squamous cell carcinoma via the PI3K/AKT and MAPK signaling pathways

Ying Sun et al. Oncol Lett. 2016 Jan.

Abstract

The present study examined the mechanisms of high mobility group box 1 (HMGB1)-induced cell migration in human cutaneous squamous cell carcinoma (CSCC) SCC13 cells. Western blotting, a chemotaxis assay and ELISA were performed to analyze HMGB1 level in SCC13 cells and its ability to regulate tumor metastasis. The results demonstrated a significantly higher level of HMGB1 in the SCC13 cell supernatant compared with the human epidermoid carcinoma A431 cell supernatant. Administration of HMGB1 to the SCC13 cells caused cell migration, which occurred in a time- and dose-dependent manner. Moreover, HMGB1 significantly activated the phosphosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) signaling pathways by an increased level of phosphorylation in p85PI3K, AKT, p38 and p42/44 MAPK. Taken together, these data suggest that HMGB1 regulates tumor metastasis in CSCC via the PI3K/AKT and MAPK signaling pathways.

Keywords: HMGB1; MAPK pathway; PI3K/AKT pathway; cutaneous squamous cell carcinoma; migration.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CSCC SCC13 cells secrete more HMGB1 than human epidermoid carcinoma A431 cells. (A) Human CSCC SCC13 and epidermoid carcinoma A431 cells were cultured with regular medium for 24 h. Following this, concentrated media was prepared, resolved by SDS-PAGE and subjected to western blot analysis of HMGB1. Results shown are representative of three independent experiments and were qualified by densitometry. *P<0.01. (B) Enzyme-linked immunosorbent assay data of the supernatant showing the HMGB1 concentration in the two different cell lines. Data from three independent experiments were pooled together. CSCC, cutaneous squamous cell carcinoma; HMGB1, high-mobility group box 1.
Figure 2.
Figure 2.
HMGB1 induces the cell migration of human CSCC cells. (A) CSCC SCC13 cells were treated for the indicated times (3, 6 and 12 h). The number of migrated cells were counted and the results expressed as the mean number of migrated cells ± SEM/microscopic field (n=3). A significantly higher level of cell migration was found at the 12-h time-point (*P<0.05, ****P<0.0001). (B) The SCC13 cells were treated with the indicated concentration of HMGB1 for 12 h. The number of migrated cells was counted and the results expressed as the mean number of migrated cells ± SEM/microscopic field (n=3). A significantly higher level of cell migration was found at a HMGB1 concentration of 100 ng/ml (****P<0.0001). CSCC, cutaneous squamous cell carcinoma; HMGB1, high-mobility group box 1.
Figure 3.
Figure 3.
PI3K/AKT and MAPK signaling pathways are involved in HMGB1-induced migration. CSCC SCC13 cells were treated with/without HMGB1 (100 ng/ml) or GR (100 µM) for 24 h. At the end of treatment, the activation [phosphorylation (P)] of AKT, p85 PI3K, p38 and p42/44 MAPK was analyzed by western blotting. The whole cell lysates were prepared, resolved by SDS-PAGE and subjected to western blot analysis. The total (T)-AKT, −p85 PI3K, −p38 and −p42/44 MAPK were used as a loading control. Results shown are representative of three independent experiments and were qualified by densitometry. (A) AKT and p85 PI3K; (B) p38 MAPK and p42/44 MAPK. CSCC, cutaneous squamous cell carcinoma; HMGB1, high-mobility group box 1; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; GR, glycyrrhizin.

Similar articles

Cited by

References

    1. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011;207:337–342. doi: 10.1016/j.prp.2011.03.002. - DOI - PubMed
    1. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957–966. doi: 10.1016/j.jaad.2012.11.037. - DOI - PubMed
    1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283–287. doi: 10.1001/archdermatol.2010.19. - DOI - PubMed
    1. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg. 2002;28:268–273. doi: 10.1097/00042728-200203000-00014. - DOI - PubMed
    1. Czarnecki D, Staples M, Mar A, Giles G, Meehan C. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology. 1994;189:52–54. doi: 10.1159/000246783. - DOI - PubMed

LinkOut - more resources